ONCOSIL MEDICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | 0.00% |
|
+25.00% | -44.44% |
Valuation
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 143.6 | 33.43 | 95.29 | 42.26 | 39.65 | 23.71 |
| Enterprise Value (EV) 1 | 128.4 | 25.74 | 74.4 | 30.5 | 28.67 | 14.49 |
| P/E ratio | -13.9 x | -3.89 x | -17.7 x | -4.14 x | -3.02 x | -1.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 32.3 x | 9.22 x | 34.5 x | 32.5 x | 37.3 x | 16.2 x |
| EV / Revenue | 28.9 x | 7.1 x | 26.9 x | 23.5 x | 27 x | 9.87 x |
| EV / EBITDA | -14.9 x | -2.94 x | -16.8 x | -2.9 x | -2.72 x | -1.28 x |
| EV / FCF | -24.5 x | -5.86 x | -24.8 x | -5.93 x | -4.55 x | -2.03 x |
| FCF Yield | -4.08% | -17.1% | -4.03% | -16.9% | -22% | -49.3% |
| Price to Book | 7.91 x | 3.13 x | 4.35 x | 3.61 x | 3.55 x | 2.4 x |
| Nbr of stocks (in thousands) | 624,159 | 630,709 | 828,601 | 797,343 | 991,242 | 1,975,841 |
| Reference price 2 | 0.2300 | 0.0530 | 0.1150 | 0.0530 | 0.0400 | 0.0120 |
| Announcement Date | 8/22/18 | 8/22/19 | 8/19/20 | 8/18/21 | 8/30/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.448 | 3.626 | 2.764 | 1.298 | 1.063 | 1.467 |
| EBITDA 1 | -8.601 | -8.747 | -4.419 | -10.51 | -10.55 | -11.32 |
| EBIT 1 | -8.641 | -8.786 | -4.446 | -10.54 | -10.58 | -11.34 |
| Operating Margin | -194.29% | -242.29% | -160.86% | -811.96% | -994.72% | -772.48% |
| Earnings before Tax (EBT) 1 | -8.54 | -8.567 | -4.262 | -10.43 | -10.73 | -11.34 |
| Net income 1 | -8.54 | -8.567 | -4.262 | -10.43 | -10.73 | -11.34 |
| Net margin | -192% | -236.25% | -154.2% | -803.61% | -1,008.73% | -772.98% |
| EPS 2 | -0.0166 | -0.0136 | -0.006499 | -0.0128 | -0.0132 | -0.0100 |
| Free Cash Flow 1 | -5.233 | -4.394 | -2.999 | -5.144 | -6.296 | -7.144 |
| FCF margin | -117.65% | -121.19% | -108.52% | -396.19% | -592.09% | -486.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/22/18 | 8/22/19 | 8/19/20 | 8/18/21 | 8/30/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 15.2 | 7.69 | 20.9 | 11.8 | 11 | 9.22 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.23 | -4.39 | -3 | -5.14 | -6.3 | -7.14 |
| ROE (net income / shareholders' equity) | -60.4% | -59.4% | -26.2% | -62.1% | -93.8% | -108% |
| ROA (Net income/ Total Assets) | -34.1% | -34.8% | -15.6% | -34.5% | -48.6% | -57.7% |
| Assets 1 | 25.05 | 24.61 | 27.4 | 30.25 | 22.08 | 19.65 |
| Book Value Per Share 2 | 0.0300 | 0.0200 | 0.0300 | 0.0100 | 0.0100 | 0.0100 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0300 | 0.0200 | 0.0100 | 0 |
| Capex 1 | 0.01 | 0.01 | 0.02 | 0.05 | 0.01 | 0.06 |
| Capex / Sales | 0.24% | 0.41% | 0.75% | 4.16% | 0.55% | 3.94% |
| Announcement Date | 8/22/18 | 8/22/19 | 8/19/20 | 8/18/21 | 8/30/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.44% | 7.32M | |
| +34.00% | 704B | |
| +29.29% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +13.79% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- OSL Stock
- Financials OncoSil Medical Limited
